Investors wanting to buy into the high-growth biotech industry without purchasing shares of individual companies have had limited choices of exchange traded funds (ETFs). Read More
Priority review vouchers (PRVs) are intended to encourage the development of new therapies for underserved disease areas, such as tropical diseases and rare pediatric diseases by shaving four months off the normal 10-month period the FDA takes to conduct its drug review. Read More
In the first part of our analysis on the public biopharmaceutical companies presenting data at the ASCO meeting, covering the week the conference abstracts were released (May 11 - 15), we discovered that overall those abstract data did help improve company stock valuations, and, as a group, an average 3.2 percent increase in share price was recorded. Read More
